Kairos Pharma, Ltd.
KAPA
$0.85
-$0.01-1.05%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.69% | -12.68% | -28.78% | 6.40% | -313.83% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -100.00% | 194.87% |
| Total Other Non-Cash Items | -46.91% | 1,709.21% | 130.04% | -144.31% | 2,955.00% |
| Change in Net Operating Assets | 73.68% | -284.72% | 170.82% | 64.10% | -6,634.62% |
| Cash from Operations | -4.10% | -12.75% | 60.40% | 10.74% | -1,102.38% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 1,415.25% | -- | -- | -100.00% | -60.78% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | -- | 100.00% | -840.43% |
| Cash from Financing | 1,415.25% | -92.71% | 2,253.52% | -102.72% | 3,400.67% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 536.60% | -124.83% | 220.51% | -160.86% | 16,921.05% |